pubmed-article:3014173 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0014508 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0022877 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0086231 | lld:lifeskim |
pubmed-article:3014173 | lifeskim:mentions | umls-concept:C0765250 | lld:lifeskim |
pubmed-article:3014173 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:3014173 | pubmed:dateCreated | 1986-7-31 | lld:pubmed |
pubmed-article:3014173 | pubmed:abstractText | The enzyme immunoassays (EIAs) for antibody to human T-cell lymphotropic virus type III (HTLV-III) were rapidly adopted for screening donated blood and plasma. To evaluate the significance of a positive EIA reaction, test performance was examined in a blood bank screening program. Specimens were tested by EIA, Western blot assay, and HTLV-III/lymphadenopathy-associated virus (LAV) culture. The EIA was positive in 0.25% of 67 190 blood donations. Specimens were categorized and 57.3% had low (weak) reactivity, 12.7% had moderate reactivity, and 30.0% had high reactivity. Highly reactive specimens were strongly associated with a positive Western blot or culture (86.7%) in contrast to moderately and weakly reactive specimens (1.9%). Twenty-five of 29 donors interviewed with a highly reactive EIA had risk factors for HTLV-III/LAV infection. Risk factors were not identified for 74 of 75 interviewed donors with specimens of lower reactivity. The minimum calculated specificity was 99.82%. The use of the HTLV-III EIA has virtually eliminated the use of blood and plasma from HTLV-III/LAV infected donors. | lld:pubmed |
pubmed-article:3014173 | pubmed:language | eng | lld:pubmed |
pubmed-article:3014173 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3014173 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:3014173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3014173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3014173 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:3014173 | pubmed:month | Jul | lld:pubmed |
pubmed-article:3014173 | pubmed:issn | 0098-7484 | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:WardJ WJW | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:AllenJ RJR | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:FeorinoP MPM | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:GrindonA JAJ | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:ParvinMM | lld:pubmed |
pubmed-article:3014173 | pubmed:author | pubmed-author:SchableCC | lld:pubmed |
pubmed-article:3014173 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:3014173 | pubmed:day | 18 | lld:pubmed |
pubmed-article:3014173 | pubmed:volume | 256 | lld:pubmed |
pubmed-article:3014173 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:3014173 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:3014173 | pubmed:pagination | 357-61 | lld:pubmed |
pubmed-article:3014173 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:meshHeading | pubmed-meshheading:3014173-... | lld:pubmed |
pubmed-article:3014173 | pubmed:year | 1986 | lld:pubmed |
pubmed-article:3014173 | pubmed:articleTitle | Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. | lld:pubmed |
pubmed-article:3014173 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3014173 | lld:pubmed |